Bayer Taps New CEO

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

Bayer has announced that Marijn Dekkers, PhD, will succeed Werner Wenning as CEO starting October 1, 2010.

Bayer has announced that Marijn Dekkers, PhD, will succeed Werner Wenning as CEO starting October 1, 2010. Dr. Dekkers will join the company's board at the start of 2010 and will also serve as CEO of Bayer's healthcare division. He is currently president and CEO of Thermo Fisher Scientific.

Articles in this issue
Cancer, not HPV vaccination, hastened death of UK girl
Obesity hinders treatment in pediatric leukemia
Posaconazole reduces infection in AML patients
Global report warns of escalating cancer rate
Antidepressants continue to show increased inhibition of colorectal tumor cell growth
New class of alpha emitters takes aim at bone metastases
Who's News
Stop and smell the volatile organic compounds in lung ca
Proton therapy report advises caution
From anthracyclines to anti-VEGF: Shifts in the adjuvant treatment of breast cancer
Will Chemoradiotherapy End Surgical Dominance in the Treatment of Squamous Cell Head and Neck Cancers
Circulating tumor cells edge out imaging in breast mets
Smoking cessation requires unremitting reinforcement
Industry Watch
Avastin Breast Rx Trial Enrollment Halted Due to Cardiotoxicity Cases
Recent Videos
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
Related Content
PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

Ariana Pelosci
October 22nd 2024
Article

The FDA has pushed back PDUFA dates for sotorasib and obeticholic acid for metastatic CRC and primary biliary cholangitis indications.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

The agency places a partial clinical hold on the phase 3 PRESERVE-003 trial due to varying results between the squamous and nonsquamous NSCLC cohorts.

FDA Places Partial Clinical Hold on Phase 3 Gotistobart NSCLC Trial

Russ Conroy
October 21st 2024
Article

The agency places a partial clinical hold on the phase 3 PRESERVE-003 trial due to varying results between the squamous and nonsquamous NSCLC cohorts.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.

MTX110 May Show Survival Benefits in Recurrent Glioblastoma

Russ Conroy
October 20th 2024
Article

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.

Offering certain radiotherapy modalities based on disease burden may play a role in the outcomes of those with ES-SCLC, according to James Ninia, MD.

Complete Consolidative Radiotherapy May Have Survival Benefits in ES-SCLC

Russ Conroy
October 19th 2024
Article

Offering certain radiotherapy modalities based on disease burden may play a role in the outcomes of those with ES-SCLC, according to James Ninia, MD.